<DOC>
	<DOCNO>NCT00977483</DOCNO>
	<brief_summary>To assess clinical efficacy safety long-term orally administer thioctic acid treatment diabetic polyneuropathy .</brief_summary>
	<brief_title>Assessment Efficacy Safety Thioctic Acid Oral Treatment Diabetic Polyneuropathy ( Stage 1 2 )</brief_title>
	<detailed_description>Stage 1 2a diabetic ( poly ) neuropathy ( DNP ) ( Appendix 3 ) patient diabetes mellitus ( type I II ) ; neuropathy impairment score lower limb , enlarge 7 objective item ( NISLL+7 ) ≥ 97.5 percentile ( correspond 4.43 score point ) ; total symptom score foot ( TSSfeet ) ≤ 5 .</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>1 . Signed Informed Consent . Patients must willingness complete competence cooperate language barrier must preclude adequate understanding 2 . Diabetes mellitus ( Type I II ) , define American Diabetes Association 1997 , last &gt; 1 year 3 . Males females 18 64 year ( old patient exclude agerelated change reflex , quantitative sensory test endpoint , nerve conduction endpoint ) 4 . Patient must symmetric sensorymotor peripheral polyneuropathy attributable diabetes mellitus follow thorough evaluation cause neuropathy determine perform complete medical neurological examination include physical neurological history , history medication , history exposure toxins , laboratory study 5 . Severity diabetic polyneuropathy must Stage 1 2a 6 . Insulin regimen , weight , diet , activity level must relatively stable opinion investigator ( example , HbA1C must vary ± 2 Vol. % within 6 month precede study i.e . index measure = 10 % range would 812 % ) 7 . NIS [ LL ] +7 test ≥ 97.5 percentile ( correspond 4.43 transform score point ) 8 . NIS [ LL ] ≥ 2 point ( NIS [ LL ] base question 1724 , 28 , 29 , 34 , 35 , 37 NIS ) 9 . One following : abnormality nerve conduction attribute two separate nerve , i.e . ≥99th percentile DL ≤1st percentile NCV amplitude abnormality HRDB , i.e . ≤ 1st percentile 10 . TSS ( foot ) ≤5 11 . Females must either surgically sterilise ( tubal ligation , bilateral oophorectomy , hysterectomy ) least 1 year postmenopausal practice acceptable method contraception , include oral contraceptive stable regimen least two month , depomedroxyprogesterone , barrier method alone ( diaphragm , condom , contraceptive sponge spermicidals ) , IUD place least two month 1 . Patients proximal asymmetric neuropathy , cranial neuropathy , truncal radiculopathy , pan dysautonomia , diabetic plexopathies , acute active mononeuropathy ( include cranial neuropathy , postherpetic neuralgia , etc . ) , presence might obscure accurate assessment severity diabetic polyneuropathy assessment , exception carpal tunnel syndrome ( CTS ) tardy ulnar neuropathy ( TUN ) 2 . Neuropathy cause diabetes mellitus might interfere assessment severity dPNP Other neurologic disease may produce weakness , sensory loss , autonomic symptom test abnormality might interfere assessment severity dPNP Myopathy cause might interfere assessment severity dPNP 3 . Peripheral vascular disease severe enough cause intermittent claudication ischemic ulcer limb ischemia 4 . Patients history ophthalmological finding suggest high risk visual loss i.e. , significant maculopathy proliferative retinopathy 5 . Psychiatric , psychological , behavioural symptom would interfere patient 's ability participate trial 6 . Patients active neoplastic disease except basal cell carcinoma 7 . Patients atrial fibrillation unless control stabilised medication ( change criterion Amendment 1 ) 8 . Patients clinically significant cardiac , pulmonary , gastrointestinal , hematologic , endocrine disease ( diabetes ) may confound interpretation study result prevent patient complete study 9 . Patients organ transplant kind 10 . Patients significant hepatic renal disease ( ASAT ALAT &gt; 2 time normal , serum creatinine &gt; 1.8 mg/dL ( &gt; 159 µmol/l ) males &gt; 1.6 mg/dL ( &gt; 141 µmol/l ) females ) 11 . Patients recent history ( within last 12 month ) drug alcohol abuse 12 . Use investigational drug within last 6 month 13 . History severe anaphylactic reaction multiple drug , sulfur product , biologic product ( change criterion Amendment 1 ) 14 . Ketoacidosis hypoglycaemia within last 3 month result hospital admission 15 . Antioxidant therapy ( vitamin E &gt; 400IU , C &gt; 200mg , betaCarotene &gt; 30mg ) pentoxyphylline within last 1 month start trial 16 . Use even primrose oil gammalinolenic acid contain substance within last 3 month 17 . Use thioctic acid &gt; 50mg/day within last 3 month 18 . History use medication vitamin know cause peripheral neuropathy include limited use phenytoin carbamazepine 15 year , use pyridoxine &gt; 100mg/d within past 12 month 19 . Bilateral sural nerve biopsy 20 . Existing foot ulcer 21 . Pregnant lactating female 22 . Continued use medication list protocol 6.3.3 ( first paragraph ) 23 . Medication noncompliance ( deviation ±10 % dosages take ( 1 tablet/day ) )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>